BioSpace News Archive

Rockwell Medical, Inc. announced that Russell Ellison, M.D., M.Sc., President and Chief Executive Officer is scheduled to present at H.C. Wainwright’s Annual Global Life Sciences Conference in Miami, Florida on Tuesday, May 24th at 3:30 PM ET.

OncoSec Medical Incorporated announced that it is the recipient of the 2022 Vanguard Award presented by the Triple Negative Breast Cancer Foundation.

Teva Presents New Long-Term AUSTEDO ® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting.

Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA ® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer.

Biotricity Inc. is scheduled to present and will be participating in a fireside chat at the H.C. Wainwright Global Investment Conference, being held from May 23-26, 2022.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferences.

Anokion SA announced positive clinical trial results from the company’s Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial evaluating its lead candidate, KAN-101.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has acquired Satiogen Pharmaceuticals, Inc., a San Diego-based company. Satiogen, now a wholly-owned Mirum subsidiary, was an existing licensing partner for LIVMARLI® (maralixibat) oral solution and volixibat.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that Bentrio has been approved by the Philippines’ Food and Drug Administration (FDA) and is now cleared for commercialization in that country of 115 million people.